Giulia Milardi graduated in Medical, Molecular and Cellular Biotechnologies at the University Vita-Salute San Raffaele of Milan in 2019 and she carried out her Master’s thesis in gene therapy, working on a rare disorder caused by adenosine deaminase 2 (ADA2) deficiency. In the same year, she obtained a qualification as a professional biologist at the University of Pavia. As a post-graduate fellow, she worked on follicular helper T cells of patients affected by Common Variable Immunodeficiency (CVID), spending a period at the National Institutes of Health (NIH) in the USA.

She obtained her PhD in Humanitas University, studying the nature, phenotype and functional properties of B lymphocytes and their subpopulations in the tumor microenvironment of Cholangiocarcinoma, with the goal of funding new mechanisms important for cancer progression or control that could be exploited to develop novel immunotherapeutic approaches. During her Ph.D., she obtained the fellowship Italy Pre-Doc 2022, issued by AIRC – Fondazione AIRC per la Ricerca sul Cancro.

She is now a postdoc fellow at the Precision Medicine Lab led by Prof. Salvatore Piscuoglio.